The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review
Frontiers in Psychiatry · 27.04.2023 · 14
DOI: 10.3389/fpsyt.2023.1141836 ↗Kurz gefasst
Scoping Review in der Zeitschrift Frontiers in Psychiatry, online erschienen am 27.04.2023. Verfasst von Charlotte E Goldfine und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, United States. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Introduction
Alcohol use disorder (AUD) is the most prevalent substance use disorder (SUD) globally. In 2019, AUD affected 14.5 million Americans and contributed to 95,000 deaths, with an annual cost exceeding 250 billion dollars. Current treatment options for AUD have moderate therapeutic effects and high relapse rates. Recent investigations have demonstrated the potential efficacy of intravenous ketamine infusions to increase alcohol abstinence and may be a safe adjunct to the existing alcohol withdrawal syndrome (AWS) management strategies.
Methods
We followed Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines to conduct a scoping review of two databases (PubMed and Google Scholar) for peer-reviewed manuscripts describing the use of ketamine in AUD and AWS. Studies that evaluated the use of ketamine in AUD and AWS in humans were included. We excluded studies that examined laboratory animals, described alternative uses of ketamine, or discussed other treatments of AUD and AWS.
Results
We identified 204 research studies in our database search. Of these, 10 articles demonstrated the use of ketamine in AUD or AWS in humans. Seven studies investigated the use of ketamine in AUD and three studies described its use in AWS. Ketamine used in AUD was beneficial in reducing cravings, alcohol consumption and longer abstinence rates when compared to treatment as usual. In AWS, ketamine was used as an adjunct to standard benzodiazepine therapy during severe refractory AWS and at signs of delirium tremens. Adjunctive use of ketamine demonstrated earlier resolution of delirium tremens and AWS, reduced ICU stay, and lowered likelihood of intubation. Oversedation, headache, hypertension, and euphoria were the documented adverse effects after ketamine administration for AUD and AWS.
Conclusion
The use of sub-dissociative doses of ketamine for the treatment of AUD and AWS is promising but more definitive evidence of its efficacy and safety is required before recommending it for broader clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, United States.
- Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States.
- Center for Brain Circuit Therapeutics, Brigham and Women's Hospital, Boston, MA, United States.
- The Fenway Institute, Fenway Health, Boston, MA, United States.
- Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Boston, MA, United States.
Förderung
- NIMH NIH HHS
Zitieren
APA
Goldfine, C. E., Tom, J. J., Im, D. D., Yudkoff, B., Anand, A., Taylor, J. J., Chai, P. R., & Suzuki, J. (2023). The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1141836
Vancouver
Goldfine CE, Tom JJ, Im DD, Yudkoff B, Anand A, Taylor JJ, et al. The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1141836
BibTeX
@article{Goldfine2023,
author = {Goldfine, Charlotte E and Tom, Jeremiah J and Im, Dana D and Yudkoff, Benjamin and Anand, Amit and Taylor, Joseph J and Chai, Peter R and Suzuki, Joji},
title = {The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review},
journal = {Frontiers in Psychiatry},
year = {2023},
volume = {14},
doi = {10.3389/fpsyt.2023.1141836}
}
EUVIMED